Vertex Pharmaceuticals Inc (VRTX) stock
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3028% above fair value
$547.03−0.86 (-0.16%)
Close on Nov 11, 2026Market cap $138.65BP/E 31.8Yield –
Vertex Pharmaceuticals enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Vertex Pharmaceuticals's enterprise value was $130.74B on Nov 11, 2026, against $103.83B a year earlier. Over the last 5 years it ranged from $49.30B to $133.74B, with a median of $97.27B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $130.74B | +20.1% |
| 2025 | Dec 31, 2025 | $108.84B | +11.9% |
| 2024 | Dec 31, 2024 | $97.27B | +4.6% |
| 2023 | Dec 29, 2023 | $92.98B | +44.5% |
| 2022 | Dec 30, 2022 | $64.34B | +30.5% |
| 2021 | Dec 31, 2021 | $49.30B | -10.9% |
| 2020 | Dec 31, 2020 | $55.34B | +5.7% |
| 2019 | Dec 31, 2019 | $52.33B | +33.1% |
| 2018 | Dec 31, 2018 | $39.33B | +7.8% |
| 2017 | Dec 29, 2017 | $36.49B | +105.7% |
| 2016 | Dec 30, 2016 | $17.74B | -41.5% |
| 2015 | Dec 31, 2015 | $30.31B | +8.9% |
| 2014 | Dec 31, 2014 | $27.82B | +64.1% |
| 2013 | Dec 31, 2013 | $16.95B | +92.1% |
| 2012 | Dec 31, 2012 | $8.83B | +35.9% |
| 2011 | Dec 30, 2011 | $6.49B | -0.8% |
| 2010 | Dec 31, 2010 | $6.54B | +16.2% |
| 2009 | Dec 31, 2009 | $5.63B | – |
See a number that looks wrong?